title: The effect of magnesium sulfate treatment on blood biochemistry and bleeding time in patients with severe preeclampsia.
abstract: OBJECTIVE
  The objective of this study was to observe the effects of magnesium sulfate on various blood biochemical parameters and coagulation status of patients with preeclampsia.
  
  
  METHODS
  During a period of 4 years, 50 patients with severe or mild preeclampsia progressing to severe preeclampsia were included in the cross-sectional study. Prothrombine (PT), activated limited thromboplastin time (aPTT), magnesium level, biochemistry parameters, systolic, and diastolic blood pressure (BP) were measured. These parameters were remeasured in the second hour of magnesium sulfate treatment.
  
  
  RESULTS
  After magnesium sulfate therapy; creatinine levels are decreased (p < 0.05), bleeding time is increased and serum magnesium levels are increased (p < 0.01), systolic and diastolic BP values decreased significantly (p < 0.01). PT, aPTT, platelet levels, and coagulation time did not change after treatment.
  
  
  CONCLUSIONS
  Magnesium sulfate infusion prolonged bleeding time in patients with severe preeclampsia. This is clinically important because it worsens the present condition and causes possible complications.
authors.affiliation: SB Istanbul Goztepe Education and Research Hospital, Istanbul, Turkey.
authors.forename: Kadir
authors.initials: K
authors.lastname: Guzin
authors.forename: Gokhan
authors.initials: G
authors.lastname: Goynumer
authors.forename: Fulya
authors.initials: F
authors.lastname: Gokdagli
authors.forename: Engin
authors.initials: E
authors.lastname: Turkgeldi
authors.forename: Gunes
authors.initials: G
authors.lastname: Gunduz
authors.forename: Furkan
authors.initials: F
authors.lastname: Kayabasoglu
mesh_terms: D000927:Anticonvulsants / Q000009:adverse effects / Q000627:therapeutic use; D001671:Biochemistry; D001724:Birth Weight / Q000187:drug effects; D001760:Bleeding Time; D001774:Blood Chemical Analysis; D001794:Blood Pressure / Q000187:drug effects; D003430:Cross-Sectional Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007226:Infant Mortality; D007231:Infant, Newborn; D008278:Magnesium Sulfate / Q000009:adverse effects / Q000627:therapeutic use*; D011225:Pre-Eclampsia / Q000097:blood* / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011247:Pregnancy; D047928:Premature Birth / Q000453:epidemiology; D012720:Severity of Illness Index
chemical_list: D000927:Anticonvulsants; D005343:Fibrinolytic Agents; D008278:Magnesium Sulfate